| 1 |
30875928 | Newer-Generation EGFR Inhibitors in Lung Cancer: How Are They Best Used? | 2019 Mar 15 |
2 |
| 2 |
29331646 | Progress in the Management of Advanced Thoracic Malignancies in 2017. | 2018 Mar |
2 |
| 3 |
29883838 | Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors. | 2018 Sep |
1 |
| 4 |
30957057 | Acquired ALK and RET Gene Fusions as Mechanisms of Resistance to Osimertinib in EGFR-Mutant Lung Cancers. | 2018 |
1 |
| 5 |
28007627 | Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs). | 2017 Apr |
1 |
| 6 |
26620497 | Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches. | 2016 Apr |
2 |